Entrada Therapeutics, Inc. · NASDAQ:TRDA
Entrada Therapeutics — CureDuchenne Futures 2022
10 slides from Entrada Therapeutics's conference presentation, 2022
Slide 1: Endosomal Escape Vehicle (EEV) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy
Endosomal Escape Vehicle (EEVTM) Platform for Delivery of Oligonucleotides in Duchenne Muscular Dystrophy Nerissa Kreher, MD, MBA Chief Medical Officer Entrada Therapeutics, Inc. 1 CureDuchenne Futures 2022
Slide 2: Disclaimer
DISCLAIMER This presentation includes express and implied “forward-looking statements. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,
Slide 3: Our Commitment to the DMD Community
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx OUR COMMITMENT TO THE DMD COMMUNITY At the heart of our work to bring innovative therapies to people living with devastating diseases are our partnerships with community leaders and patient advocacy organizat
Slide 4: A Discovery Engine for Intracellular Therapeutics
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx A DISCOVERY ENGINE FOR INTRACELLULAR THERAPEUTICS 75% of all disease-causing targets are located inside of cells, yet most are still considered inaccessible • Oligonucleotides offer a therapeutic approach to
Slide 5: Endosomal Escape Vehicle (EEV) Platform
ENDOSOMAL ESCAPE VEHICLE (EEV™) PLATFORM We are developing EEV-oligonucleotide conjugates for the treatment of individuals with DMD • Entrada’s EEV™ platform consists of a library of proprietary cyclic peptides with unique chemistry that enable improved uptake into the cell and escape from the endos
Slide 6: Our Technology Produces Exon Skipping and Dystrophin Production in a DMD Mouse Model
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx OUR TECHNOLOGY PRODUCES EXON SKIPPING AND DYSTROPHIN PRODUCTION IN A DMD MOUSE MODEL Heart Diaphragm Tibialis Anterior **** Robust exon 23 skipping 100 **** 100 **** 120 **** was observed after four **** ****
Slide 7: Treatment of Mice with EEV-PMO Reverses Muscle Damage and Improves Muscle Function
TREATMENT OF MICE WITH EEV-PMO REVERSES MUSCLE DAMAGE AND IMPROVES MUSCLE FUNCTION D2-mdx mice treated with our EEV-PMO-23 showed reduced muscle damage (lower CK levels) and significant improvements in muscle function when compared to unconjugated PMO-23 Serum CK (Muscle Damage) Wire Hang Time Grip
Slide 8: ENTR-601-44 Is Our Clinical Candidate for Individuals Amenable to Exon 44 Skipping
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx ENTR-601-44 IS OUR CLINICAL CANDIDATE FOR INDIVIDUALS AMENABLE TO EXON 44 SKIPPING A single IV dose of ENTR-601-44 resulted in robust exon skipping in both skeletal and cardiac muscles in non-human primates (
Slide 9: ENTR-601-44: Current Clinical Development Plan for Exon 44 Skipping
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx ENTR-601-44: CURRENT CLINICAL DEVELOPMENT PLAN FOR INDIVIDUALS AMENABLE TO EXON 44 SKIPPING First-in-Human Trial Multiple Ascending Dose/Phase 2b Single Ascending Dose Study* Multiple Ascending Dose Study* Ph
Slide 10: Thank You from Team Entrada
ibdroot\projects\IBD-NY\emeer2021\674882_1\TTW Deck\Entry TTW Shell_27-Aug-2021_RB_v10.pptx THANK YOU FROM TEAM ENTRADA! Come Visit Us at Booth 11! We look forward to working with you! 10 CureDuchenne Futures 2022